Sarah Wilkens

Multi-institutional outcomes of Impella use in pediatric patients: A brief communication from the ACTION Network

In this multicenter retrospective study of 150 pediatric patients supported with the Impella device, 89.3% achieved positive clinical outcomes despite a 28% adverse event rate. Findings suggest a potential role for Impella in managing refractory advanced heart failure in children, particularly those with cardiomyopathy, transplant graft dysfunction, or congenital heart disease.

Multi-institutional outcomes of Impella use in pediatric patients: A brief communication from the ACTION Network Read More »

Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy

In a prospective study of 265 males with Duchenne Muscular Dystrophy, nearly 30% of those with moderate or severe heart dysfunction were not receiving full consensus-directed cardiac therapy, and most did not reach target medication doses—highlighting the need to optimize treatment strategies as cardiac disease becomes a leading cause of death in DMD.

Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy Read More »

Ventricular assist device implantation in children with a mechanical valve: An ACTION registry analysis

Patients with congenital heart disease (CHD) frequently have had valve interventions, including replacement with a mechanical valve. The impact of a mechanical valve on clinical outcomes in patients undergoing ventricular assist device (VAD) implantation is not well characterized.

Ventricular assist device implantation in children with a mechanical valve: An ACTION registry analysis Read More »